International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Osteoporosis International

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s00198-014-2883-2PMID 25257932PMCID PMC4873770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database

  2016cited by this paper
• Glucocorticoid-induced osteoporosis

  2015cited by this paper
• Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis

  2015cited by this paper

• How to optimize the use of anti-osteoporotic medication in clinical practice?

  2025cites this paper
• Comparative Bone-Protective Effects of Tocotrienol Isomers from Palm and Annatto in Dexamethasone-Induced Osteoporotic Male Rats

  2025cites this paper
• Mind the bone: a protocol for osteoporosis prophylaxis in patients with thyroid eye disease on intravenous methylprednisolone

  2025cites this paper
• Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review

  2025cites this paper
• Capacity for and Utilization of Dual‐Energy X‐Ray Absorptiometry Within the Veterans Health Administration

  2025cites this paper
• The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena

  2024influential citation
• Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

  2024cites this paper
• Fufang Zhenshu Tiaozhi capsule enhances bone formation and safeguards against glucocorticoid-induced osteoporosis through innovative Mekk2-mediated β-catenin deubiquitination

  2024cites this paper
• Patients with osteoporosis: children of a lesser god

  2023cites this paper
• GENDER AND AGE ASPECTS IN THE PATHOGENESIS OF BONE MINERAL DENSITY DISORDERS.

  2023cites this paper
• Effects of genistein aglycone in glucocorticoid induced osteoporosis: A randomized clinical trial in comparison with alendronate.

  2023cites this paper
• Extensive Expertise in Endocrinology: Advances in the Management of Glucocorticoid-Induced Osteoporosis.

  2023cites this paper
• Glucocorticoids and Musculoskeletal Health

  2022cites this paper
• Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial

  2022cites this paper
• ԳԼՅՈՒԿՈԿՈՐՏԻԿՈԻԴ-ԻՆԴՈՒԿՑՎԱԾ ՕՍՏԵՈՊՈՐՈԶԻ ԱՐԴԻԱԿԱՆՈՒԹՅՈՒՆԸ, ԿԱՆԽԱՐԳԵԼՄԱՆ ԵՎ ԲՈՒԺՄԱՆ ԺԱՄԱՆԱԿԱԿԻՑ ՄՈՏԵՑՈՒՄՆԵՐԸ

  2022cites this paper
• Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways

  2022cites this paper
• Regulation of bone mass in endocrine diseases including diabetes.

  2022cites this paper
• Morinda officinalis polysaccharide enable suppression of osteoclastic differentiation by exosomes derived from rat mesenchymal stem cells

  2022cites this paper
• Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 1)

  2022cites this paper
• Preventive Effects of Dietaryraisins on Steroid - Induced Bone Changes in Rats

  2021cites this paper
• Sodium hydrosulfide alleviates dexamethasone-induced cell senescence and dysfunction through targeting the miR-22/sirt1 pathway in osteoblastic MC3T3-E1 cells

  2021cites this paper
• MicroRNA-22 contributes to dexamethasone-induced osteoblast differentiation inhibition and dysfunction through targeting caveolin-3 expression in osteoblastic cells

  2021cites this paper
• Management of glucocorticoid-induced osteoporosis

  2021cites this paper
• Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis

  2021cites this paper
• Rehabilitation in a case of severe osteoporosis with prevalent fractures in a patient known with multiple sclerosis and prolonged glucocorticoid therapy

  2021cites this paper
• New promising avenue for the simvastatin combination with residronate, strontium ranelate and raloxifene in experimentally-induced osteoporosis

  2020cites this paper
• Possibilities of using a FRAX® risk calculator for 10-year probability of fractures assessment in patients with rheumatoid arthritis

  2019cites this paper
• Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis

  2019cites this paper
• Protective effect of dietary oils containing omega-3 fatty acids against glucocorticoid-induced osteoporosis

  2019influential citation
• Understanding Patients’ Perspectives and Educational Needs by Type of Osteoporosis in Men and Women and People with Glucocorticosteroid-Induced Osteoporosis: A Qualitative Study to Improve Disease Management

  2019cites this paper
• Management of glucocorticoid‐induced osteoporosis: What is new?

  2019cites this paper
• THE RISK OF OSTEOPOROTIC FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF THE PROGRAM «OSTEOSCREENING RUSSIA»

  2018cites this paper
• Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy.

  2018cites this paper
• Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial

  2018cites this paper
• Glucocorticoid-induced osteoporosis: an update

  2018cites this paper
• Prophylaxe und Therapie der Glukokortikoid-induzierten Osteoporose

  2017cites this paper
• health insurance database glucocorticoid users : results from a public Osteoporosis prevention among chronic and

  2016cites this paper
• Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

  2016cites this paper
• Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database

  2016cites this paper
• The prevalence of clinical factors used for risk assessment of osteoporotic fractures

  2016cites this paper
• Glucocorticoid-induced osteoporosis

  2015cites this paper
• Food for thought

  2015cites this paper
• Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis

  2015cites this paper